Developing U.S. Oversight Strategies for Nanobiotechnology: Learning from Past Oversight Experiences

Journal of Law, Medicine and Ethics 37 (4):688-705 (2009)
  Copy   BIBTEX

Abstract

The emergence of nanotechnology, and specifically nanobiotechnology, raises major oversight challenges. In the United States, government, industry, and researchers are debating what oversight approaches are most appropriate. Among the federal agencies already embroiled in discussion of oversight approaches are the Food and Drug Administration , Environmental Protection Agency , Department of Agriculture , Occupational Safety and Health Administration , and National Institutes of Health . All can learn from assessment of the successes and failures of past oversight efforts aimed at emerging technologies. This article reports on work funded by the National Science Foundation aimed at learning the lessons of past oversight efforts. The article offers insights that emerge from comparing five oversight case studies that examine oversight of genetically engineered organisms in the food supply, pharmaceuticals, medical devices, chemicals in the workplace, and gene therapy. Using quantitative and qualitative analysis, the authors present a new way of evaluating oversight

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 94,439

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Similar books and articles

Gene Therapy Oversight: Lessons for Nanobiotechnology.Susan M. Wolf, Rishi Gupta & Peter Kohlhepp - 2009 - Journal of Law, Medicine and Ethics 37 (4):659-684.

Analytics

Added to PP
2010-09-13

Downloads
41 (#384,416)

6 months
8 (#528,674)

Historical graph of downloads
How can I increase my downloads?

Author Profiles

Susan Wolf
University of North Carolina, Chapel Hill